Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and Cell Cycle, advisor at We Fund Health. The past achievements and activities include but are not limited to drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
Vlad Gabai, Ph.D.
VP of R&D
Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.
Mr. Charles Legg
Over 20 years of successful biotech and big pharma experience ranging from program & portfolio manager at the international pharmaceutical company, Shire Pharmaceuticals, to the first full-time employee of the gene therapy startup, Solid Ventures. Successful projects in molecular diagnostics, drug discovery from early POC to pivotal clinical trials, from commercial launching to global expansion, from early seed funding to two $100MM+ IPOs. Focus on gene therapy and immuno-oncology.
Ilya Lapshin, JD
18 years of legal experience in a large New York law firm and two Massachusetts-based boutique firms helping startups and big corporate clients. Between a double major at MIT, Physics with Electrical Engineering and Math, and Boston University Law School, successful entrepreneurial and startup experience including a lucrative exit from a business, which Ilya started as a co-founder as soon as he came to the US.
Franco Venanzi, Ph.D.
Director of Basic Research
Over 30 years of biomedical research, over 20 years of tenured faculty professorship at University of Camerino, Italy, where was Head of the Translational Biology Laboratory, 20 years of service as editor-in-chief, editorial board member and a reviewer for vaccination and immunobiology journals.
Hong Li, MD, MBA, MPH, MS
Interim Clinical Director
Over 20 years extensive global clinical development and medical affairs strategic experience, outstanding proven track records in US, Europe, and Asian-pacific. As a clinical/medical/project lead, led global cross function teams to develop clinical and/or medical plans, conduct international trials across multiple therapeutic indications and cross phases 1-4 and postmarketing, to meet scientific, regulatory and commercial needs, with high quality and in a timely/on budget/scientifically responsible fashion.